These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12916502)

  • 1. Blocking lymphocyte adhesion: new treatment for sticky cases of Crohn disease?
    Rhee SJ; Bousvaros A
    J Pediatr Gastroenterol Nutr; 2003 Aug; 37(2):211-3. PubMed ID: 12916502
    [No Abstract]   [Full Text] [Related]  

  • 2. Natalizumab for induction of remission in Crohn's disease.
    MacDonald JK; McDonald JW
    Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.
    Gordon FH; Lai CW; Hamilton MI; Allison MC; Srivastava ED; Fouweather MG; Donoghue S; Greenlees C; Subhani J; Amlot PL; Pounder RE
    Gastroenterology; 2001 Aug; 121(2):268-74. PubMed ID: 11487536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA advisers endorse natalizumab for Crohn's disease.
    Traynor K
    Am J Health Syst Pharm; 2007 Sep; 64(18):1886, 1888, 1890. PubMed ID: 17823090
    [No Abstract]   [Full Text] [Related]  

  • 5. Natalizumab (Tysabri) for Crohn's disease.
    Med Lett Drugs Ther; 2008 May; 50(1285):34-6. PubMed ID: 18458669
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-adhesion molecule strategies for Crohn disease.
    Leung Y; Panaccione R
    BioDrugs; 2008; 22(4):259-64. PubMed ID: 18611068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab for induction of remission in Crohn's disease.
    Macdonald JK; McDonald JW
    Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotoxicity profile of natalizumab.
    Wehner NG; Gasper C; Shopp G; Nelson J; Draper K; Parker S; Clarke J
    J Immunotoxicol; 2009 Jun; 6(2):115-29. PubMed ID: 19589098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic therapies in inflammatory bowel disease.
    Cohen LB; Nanau RM; Delzor F; Neuman MG
    Transl Res; 2014 Jun; 163(6):533-56. PubMed ID: 24467968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binucleated lymphocytes in patients with multiple sclerosis treated with natalizumab.
    Leclerc M; Lesesve JF; Gaillard B; Troussard X; Tourbah A; Debouverie M; Daliphard S; Delmer A
    Leuk Lymphoma; 2011 May; 52(5):910-2. PubMed ID: 21314485
    [No Abstract]   [Full Text] [Related]  

  • 11. Response to Baumgart review.
    Feagan BG; Parikh A;
    Inflamm Bowel Dis; 2010 Sep; 16(9):1449. PubMed ID: 20128003
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of integrin antagonists in the treatment of inflammatory bowel disease.
    Beniwal-Patel P; Saha S
    Expert Opin Biol Ther; 2014 Dec; 14(12):1815-23. PubMed ID: 25288228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab induces and maintains remission in severe, resistant paediatric Crohn disease.
    Hadziselimovic F
    J Pediatr Gastroenterol Nutr; 2008 Feb; 46(2):208-11. PubMed ID: 18223382
    [No Abstract]   [Full Text] [Related]  

  • 14. Natalizumab therapy for moderate to severe Crohn disease in adolescents.
    Hyams JS; Wilson DC; Thomas A; Heuschkel R; Mitton S; Mitchell B; Daniels R; Libonati MA; Zanker S; Kugathasan S;
    J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):185-91. PubMed ID: 17255829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natalizumab therapy for multiple sclerosis.
    Derfuss T; Kuhle J; Lindberg R; Kappos L
    Semin Neurol; 2013 Feb; 33(1):26-36. PubMed ID: 23709210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Blocking adhesion molecules with natalizumab in multiple sclerosis].
    Schreiner B; Kieseier BC; Hartung HP; Hohlfeld R; Wiendl H
    Nervenarzt; 2005 Aug; 76(8):999-1005. PubMed ID: 15812675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natalizumab for active Crohn's disease.
    Ghosh S; Goldin E; Gordon FH; Malchow HA; Rask-Madsen J; Rutgeerts P; Vyhnálek P; Zádorová Z; Palmer T; Donoghue S;
    N Engl J Med; 2003 Jan; 348(1):24-32. PubMed ID: 12510039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukoapheresis in Crohn's disease: the final curtain?
    Peyrin-Biroulet L; Danese S
    Gut; 2013 Apr; 62(4):487-8. PubMed ID: 22892296
    [No Abstract]   [Full Text] [Related]  

  • 19. Natalizumab induction and maintenance therapy for Crohn's disease.
    Sandborn WJ; Colombel JF; Enns R; Feagan BG; Hanauer SB; Lawrance IC; Panaccione R; Sanders M; Schreiber S; Targan S; van Deventer S; Goldblum R; Despain D; Hogge GS; Rutgeerts P; ;
    N Engl J Med; 2005 Nov; 353(18):1912-25. PubMed ID: 16267322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of inflammatory bowel disease: past, present and future.
    Keyashian K; Annunziata ML; Sakuraba A; Hanauer S
    Expert Rev Clin Immunol; 2012 May; 8(4):303-5. PubMed ID: 22607175
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.